Effect of pemafibrate on hemorheology in microvessels in patients with hypertriglyceridemia associated with type 2 diabetes mellitus or metabolic syndrome

Not Applicable

• Conditions: metabolic syndrome, Hypertriglycdimia, Diabetes mellitus

• Registration Number: JPRN-UMIN000040009
• Lead Sponsor: Dokkyo Medical University Nikko Medical Center Department of cardiology medicine and nephrology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-08
• Study Completion: 2022-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

Patients judged by the Principal Investigator or Investigator (hereinafter referred to as the Principal Investigator, etc.) to be inappropriate for participation in the research

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes from baseline in whole blood transit time in micro channel array flow analyzer(MCFAN) at 16 weeks)

Secondary Outcome Measures

Name	Time	Method
Change from baseline in whole blood transit time in MCFAN at 8 weeks Leukocyte activation index (adhesive leukocyte count, difference in whole blood transit time between heparin blood collection and heparin + EDTA2Na blood collection)